News | January 14, 2008

Needle-Free System for Management of Acute Post-Operative Pain Available in Europe

January 15, 2008 - Janssen-Cilag International NV announced today IONSYS (fentanyl iontophoretic transdermal system), a new needle-free system for the management of acute post-operative pain in a hospital setting, will become available in Germany, the U.K. and Ireland this week.

These countries represent the first markets to launch this product, and additional launches in other European countries are planned for the coming months.

As a patient activated system, the fentanyl iontophoretic transdermal system does not require needles, pumps, catheters or intravenous pump stands in the management of post-operative pain. Being needle-free, the company says this treatment eliminates the risk of needle-stick injuries and infection due to analgesic administration with intravenous patient controlled analgesia (IV PCA). This system has the potential to make the administration of post-operative pain management a less time consuming task for healthcare professionals and less intrusive for patients.

The fentanyl iontophoretic transdermal system is a compact, self-contained, preprogrammed system designed to simplify the delivery of post-operative pain relief for hospitalized patients. It is small and lightweight and has an adhesive backing that securely adheres to the patient’s upper outer arm or chest. After the patient presses a button on the system, IONSYS uses a virtually imperceptible low-intensity electrical field to rapidly transport fentanyl through the skin and into the bloodstream in a technologically advanced process called iontophoresis, the company said.

The European Commission granted marketing authorization for IONSYS throughout the EU based on the findings of a comprehensive clinical trial program.

For More information: www.janssen-cilag.com

Related Content

statins, heart scan, CT scan
News | March 25, 2014
As long as inexpensive statins, which lower cholesterol, are readily available and patients do not mind taking them, it...
News | September 30, 2013
A study by Cutting Edge Information found that pharmaceutical companies measure cost per patient per month to allow...
Feature | February 21, 2013
  Time Magazine releases the dramatic findings of a months-long investigation by contributor Steven Brill into how...
Feature | April 02, 2012
It seems a picture is worth more than a thousand words for people who see evidence of coronary artery disease, the most...
News | November 18, 2011
November 17, 2011 — Westside Medical Imaging of Beverly Hills announces the availability of high resolution magnetic...
News | October 21, 2009
October 21, 2009 – King Pharmaceuticals Inc. said today the U.S. Food and Drug Administration issued a complete...
News | October 05, 2009
October 5, 2009 – A new analysis reaffirms that Lexiscan (regadenoson) Injection, the first selective A2A adenosine...
News | July 10, 2009
July 10, 2009 – New British Heart Foundation (BHF) research(1) revealed today suggests for the first time that the way...
News | April 06, 2009
April 7, 2009 - Lantheus Medical Imaging Inc. has acquired the U.S., Canadian and Australian rights to MS-325 (...
News | June 16, 2008
June 17, 2008 - One of the biggest challenges in fighting tuberculosis is simply getting patients to take their medic
Overlay Init